Vyvgart

Business

FDA Fast-Tracks Vyvgart Expansion, Spotlighting Argenx's Pipeline and Market Potential

The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.